|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 777 6 Street, NW |
Address2 | Suite 510 |
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 16032-12
|
||||||||
|
6. House ID# 314630000
|
TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Bill Head Senior Vice President |
Date | 04/20/2010 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Generic Biologics, Health Care Reform, Budget Reconciliation, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Authorized Generics, Prescription Drug Importation/Re-Importation, 340B Drug Pricing Program, and generic drugs
H.R.1427 and S.726 - Promoting Innovation and Access to Life-Saving Medicines Act, all provisions
H.R.1548 - Pathway for Biosimilars Act, all provisions
H.R.573, all provisions
S.501 - Fair Prescription Drug Competition Act, all provisions
S.882 - Drug and Device Accountability Act of 2009, Title I Subtitle A, B, C, and D and Title II
H.R. 759 - Food and Drug Administration Globalization Act of 2009, Title II
S.525, S.1232, and H.R.1298 - Pharmaceutical Market Access and Drug Safety Act of 2009
H.R.3590 - Patient Protection and Affordable Care Act, Title VII - Improving Access to Innovative Medical Therapies; Section 10609 Generic Drug Labeling
H.R.3962 - Affordable Health Care for America Act, Title I Subtitle B Part 3 Section 1149A - Payment for Biosimilar Biological Products; Title V Subtitle C Part 2 - Biosimilars
H.R.4872 - Reconciliation Bill, Section 1101, Closing the Medicare Prescription Drug "Donut Hole"
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), White House Office, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
|
Jason |
Money |
|
|
|
Charles |
Kinney |
|
|
|
Bill |
Head |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Reimbursement, Medicaid Rebates, The Deficit Reduction Act of 2006, prescription drug reimbursement, Average Manufacture Price (AMP)/AMP Publication, Expanding rebates to Part D program, generic drugs
H.R.3962 - Affordable Health Care for America Act - Title I, Subtitle E - Improvements to Medicare Part D; Title V Subtitle A - Drug Discount for Rural and Other Hospitals; 340B Program Integrity; Title VII Subtitle E - Financing;
H.R.3590 - Patient Protection and Affordable Care Act; Title II Subtitle F - Medicaid Prescription Drug Coverage; Title VII Subtitle B - More Affordable Medicines for Children and Underserved Communities
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
|
Jason |
Money |
|
|
|
Charles |
Kinney |
|
|
|
Bill |
Head |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform, Patent Settlements/Reverse Payments/Exclusionary Payments, Patent term extensions, Generic drugs
S.515, S.610 and H.R.1260 - the Patent Reform Act of 2009, all provisions
S.369 - Preserve Access to Affordable Generics Act, all provisions
H.R.1706 - Protecting Consumers Access to Generic Drugs Act of 2009, all provisions
H.R.3590 - Patient Protection and Affordable Care Act, Title VII Subtitle A - Biologics Price Competition and Innovation
H.R.3962 - Affordable Health Care for America Act, Title V Subtitle C Part 2 - Biosimilars; Subtitle C Part 1 Section 2573 - Protecting Consumer Access to Generic Drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Congressional Budget Office (CBO), Federal Trade Commission (FTC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
|
Jason |
Money |
|
|
|
Charles |
Kinney |
|
|
|
Bill |
Head |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Generic Drug User Fees, Funding for FDA, Funding for the Office of Generic Drugs, FY2011 Presidential Budget Request, FY2011 Congressional Budget and Appropriations
The President's FY2011 Budget Request to Congress
H.R.4872 - Reconciliation Bill, Closing the Medicare Prescription Drug "Donut Hole"
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Office of Management & Budget (OMB), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
|
Jason |
Money |
|
|
|
Charles |
Kinney |
|
|
|
Bill |
Head |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Free Trade Agrements - Trans Pacific Partnership, Korean Free Trade Agreement, Anti-Counterfeiting Trade Agreement (ACTA), Generic medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kathleen |
Jaeger |
|
|
|
Jason |
Money |
|
|
|
Bill |
Head |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: http://www.gphaonline.org/about-gpha/members
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |